Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon has announced positive data from preclinical studies of polycystic kidney disease demonstrating significantly reduced kidney disease following treatment with Plexxikon's novel drug candidate.
Subscribe to our email newsletter
In the preclinical study of Plexxikon’s polycystic kidney disease (PKD) drug candidate, doses of the drug candidate were administered orally daily for 14 days. A marked reduction in kidney cyst burden was observed in the treatment group compared to vehicle treated mice.
Levels of blood urea nitrogen, an indicator of kidney function, were also significantly improved in the drug-treated groups compared with the vehicle-treated group, suggesting that improved renal function accompanied reduced cyst growth in treated animals.
Plexxikon’s novel small molecule kinase inhibitor is said to be a highly selective and potent inhibitor of Raf kinase, a critical mediator of PKD pathology.